KUALA LUMPUR: Ho Wah Genting Bhd's (HWG) joint venture partner US-based E-MO Biology Inc (EBI), inked three agreements for research and development (R&D) for a potential Covid-19 vaccine.
These agreements entails the appointment of Dr John Andrews by EBI to support US Food and Drug Administration (FDA)
Investigational New Drug (IND) application for the new Covid-19 vaccine research.
EBI has also engaged the services of Roderick A Comunale II MD Inc to conduct clinical research the effects of Inactivate Polio Vaccine (IPV) in accordance to the US FDA approved protocol
Thirdly, EBI has also collaborated with America Diagnostic & Genescan Diagnostics Inc (ADGD) as a strategic partner involved with research, development and production of the companion diagnostics systems.
EBI together with ADGD will be working together to conduct a series of immunology essays in supporting the potential clinic research
HWGB chief executive officer Datuk Aaron Lim said the agreements facilitating the R&D including the clinical trials for a Covid-19 vaccine are crucial to the clinical trials.
"These agreements bring in the needed expertise that will help boost the clinical trials that must be conducted in accordance with US laws.
"We look forward to the fruitful work that will come from the collaborations with our partners and we again want to emphasise that time is important in the production of the vaccine given how the pandemic has ravaged through Southeast Asia's population and weigh on its economy," Aaron said.